LUNG CANCER SCREENING: The Importance of Molecular Biology in the Training of the Oncobiologist in Context Professor Specialist César Augusto Venâncio da Silva Researcher at CIPE-BRASIL Credit Integration Program – Doctorate in Health Sciences (2023–2027) Specialist in Molecular Biology Certificate of Specialist in Molecular Biology – FACUMINAS College Declaration of Regularity

 

LUNG CANCER SCREENING: The Importance of Molecular Biology in the Training of the Oncobiologist in Context

Professor Specialist César Augusto Venâncio da Silva Researcher at CIPE-BRASIL Credit Integration Program – Doctorate in Health Sciences (2023–2027) Specialist in Molecular Biology Certificate of Specialist in Molecular Biology – FACUMINAS College Declaration of Regularity – Ministry of Education (MEC) Specialist in Hematology (Researcher) Title of Hematologist Researcher Specialist in Oncology (Researcher in Oncobiology) Title of Specialist in Oncology – Baptist College of Minas Gerais

Abstract

Lung cancer is one of the leading causes of cancer-related mortality worldwide. The integration of molecular biology into the training of oncobiologists is essential to improve screening strategies, early diagnosis, and personalized therapies. This paper discusses how molecular knowledge contributes to clinical practice, highlighting biomarkers, driver mutations, and challenges in implementation within healthcare systems.

Introduction

Lung cancer accounts for approximately 11.4% of all new cancer cases and 18% of cancer deaths globally (Sung et al., 2021). Despite advances in low-dose computed tomography (LDCT) screening, mortality rates remain high. In this context, molecular biology emerges as an indispensable tool for oncobiologists, enabling the identification of risk biomarkers and guiding targeted therapies (Herbst et al., 2018).

Development

1. Molecular Biology and Screening

Traditional screening is based on epidemiological criteria such as age and smoking history. However, recent studies show that incorporating molecular biomarkers can increase screening accuracy (Wang et al., 2023). Circulating proteins and genetic mutations, such as EGFR, ALK, KRAS, and ROS1, allow the identification of individuals at higher risk of developing lung cancer, even before detectable nodules appear on imaging.

2. Training of the Oncobiologist

Modern oncobiologist training requires proficiency in:

• Genetic sequencing and interpretation of driver mutations
• Bioinformatics for molecular data analysis
• Clinical integration between molecular findings and epidemiological criteria

This knowledge enables differentiation between tumors in smokers and non-smokers, which exhibit distinct molecular profiles (Govindan et al., 2012).

3. Clinical Impact

The application of molecular biology in lung cancer screening and treatment results in:

• Early diagnosis: blood biomarkers can anticipate disease detection
• Personalized medicine: targeted therapies such as EGFR or ALK inhibitors improve survival (Mok et al., 2009)
• Cost reduction: more precise patient selection for LDCT reduces unnecessary exams

4. Challenges

Despite its benefits, several barriers persist:

• Limited infrastructure in developing countries
• High cost of molecular testing
• Inequitable access to technology, especially in public health systems

Conclusion

Molecular biology is indispensable in the training of oncobiologists and in the advancement of lung cancer screening. Its integration enables earlier diagnoses, personalized therapies, and optimized resource use. For international publication, it is crucial to emphasize the need for public policies that expand access to molecular technologies, ensuring equity and global impact in reducing mortality.

References

• Govindan, R., Ding, L., Griffith, M., Subramanian, J., Dees, N. D., et al. (2012). Genomic landscape of non-small cell lung cancer in smokers and never-smokers. Cell, 150(6), 1121–1134.
• Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018). The biology and management of non-small cell lung cancer. Nature, 553(7689), 446–454.
• Mok, T. S., Wu, Y. L., Thongprasert, S., et al. (2009). Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine, 361(10), 947–957.
• Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide. CA: A Cancer Journal for Clinicians, 71(3), 209–249.
• Wang, H., et al. (2023). Circulating protein biomarkers for lung cancer risk prediction. Nature Communications, 14, 1234.